Newsroom | Gilead - Gilead Sciences
Find Gilead press releases and media inquiries here.
U.S. FDA Grants Breakthrough Therapy Designation to Trodelvy ...
6 天之前 · Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19 ...
Gilead Sciences Announces Completion of Acquisition of CymaBay
2024年3月22日 · FOSTER CITY, Calif.-- (BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire CymaBay Therapeutics, Inc. (Nasdaq: CBAY) for approximately $4.3 billion in total equity value.
Gilead Sciences Announces Completion of Acquisition of CymaBay
FOSTER CITY, Calif., March 22, 2024 -- (BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire CymaBay...
Gilead Sciences (GILD) Made Big Announcements in Q3 - Yahoo …
3 小时之前 · Gilead Sciences, Inc. (NASDAQ:GILD) is a biopharmaceutical company. The one-month return of Gilead Sciences, Inc. (NASDAQ:GILD) was 2.30%, and its shares gained 16.21% of their value over the last ...
Gilead Sciences’ Buy Rating Affirmed on HIV Market Potential and ...
6 天之前 · These factors collectively justify the optimistic outlook and Buy rating for Gilead Sciences. According to TipRanks , Breen is an analyst with an average return of -5.8% and a 33.33% success rate.
Gilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief
2024年12月12日 · Gilead Sciences, Inc. today announced that Dietmar Berger, MD, PhD, will join the company on January 2, 2025, as Chief Medical Officer and will become a member of Gilead’ s senior leadership ...
Gilead Submits New Drug Application to U.S. Food and Drug ...
4 天之前 · Lenacapavir Named 2024 “Breakthrough of the Year” by Science Magazine. Foster City, Calif., December 19, 2024 – Gilead Sciences, Inc. (Nasdaq: GILD) today announced the company completed New Drug Application (NDA) submissions to the U.S. Food and Drug Administration (FDA) seeking approval of an investigational use of lenacapavir—the company’s twice-yearly injectable HIV-1 capsid ...
Gilead Sciences Announces Third Quarter 2022 Financial Results
2022年10月27日 · Oncology Sales Increased 79% Year-Over-Year to $578 million. FOSTER CITY, Calif.-- (BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the third quarter of 2022. Chairman and Chief Executive Officer of Gilead Sciences, Daniel O’Day said: “This was another very strong quarter across the business.
Gilead's breast cancer drug gets U.S. FDA approval for third …
2023年2月3日 · Gilead Sciences said on Friday the U.S. Food and Drug Administration had greenlighted the use of Trodelvy for a third indication, providing another treatment option for patients with the most...